BioLife Solutions Adopts New Brand Identity

BOTHELL, Wash., June 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the launch of its new corporate brand identity, redesigned logo, and website. The new brand identity was created to better reflect BioLife's expanded portfolio of bioproduction tools and services.

Todd Berard, Chief Marketing Officer, remarked, "We pursued a refreshed design that appropriately positions BioLife as the premier supplier of cell and gene therapy bioproduction products and services to cell therapy, gene therapy, and biopharma, and supports our entire product portfolio as we continue to execute on our M&A strategy. From the beginning, the goal was always to embrace BioLife's rich history as an innovator of biopreservation tools, and to use that history to inform design decisions. We also needed a design that works well in digital environments, leverages our historical color palette, and provides flexibility for future growth, and this new design does that nicely."   

Michael Clarke, Global Creative Director, also commented, "We set out to create a design that works on multiple levels, while also speaking with a strength and clarity that reflects the purposefulness of our mission. Our new identity features a design that can be interpreted both as a two-dimensional and three-dimensional form — with directional arrows radiating from a single point to represent segments of the bioproduction workflow, and an alternate three-dimensional view representing a single cell shielded by the walls of a 3D cube. As our business has grown to provide a broader, more comprehensive array of solutions, we wanted to craft a visual identity that would be more than the sum of its parts and represent the core mission of preserving live biologic materials as well as conveying multiple dynamic areas of activity."

The new BioLife corporate website launched this week with this new visual identity and includes the full website integration of several companies previously acquired by BioLife. It also includes enhanced e-commerce capabilities, a much broader product catalog, enhanced security, and advanced integrations to other aspects of our business. Please visit us at www.biolifesolutions.com.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Our portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, Custom Biogenic Systems® high-capacity cryogenic freezers, Stirling Ultracold® ULT freezers, and SciSafe® biologic materials storage. For more information, please visit www.biolifesolutions.com, www.scisafe.com, and www.stirlingultracold.com, and follow BioLife on Twitter

Media & Investor Relations

Roderick de Greef
Chief Financial Officer
(425) 686-6002
rdegreef@biolifesolutions.com

 

 

SOURCE BioLife Solutions, Inc.

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Insights

May 21, 2025

Designing the Ideal Cryostorage Container for CGT

April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Preserve, protect and expand cell performance

Mastering
Biopreservation

Ensure Regulatory Submission Readiness

Automate & Close
CGT Processes

Protect & Expand
Cell Performance